08:11 AM EST, 12/02/2024 (MT Newswires) -- Zai Lab ( ZLAB ) and NovoCure ( NVCR ) said Monday that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.

NovoCure ( NVCR ) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab ( ZLAB ) plans to file for regulatory approval in China, the companies said

Novocure ( NVCR ) shares rose by more than 25% in premarket trading, while Zai Lab ( ZLAB ) was up about 2%.